Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: Impact on metabolic and reproductive abnormalities

Treatments in Endocrinology

Volumn 5, Issue 3, 2006, Pages 171-187

  Elkind Hirsch, Karen E ^a  

^a Woman's Health Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; ANTIESTROGEN; BIGUANIDE DERIVATIVE; CLOMIFENE; CYPROTERONE; DEXAMETHASONE; EFLORNITHINE; ESTROGEN; ETHINYLESTRADIOL PLUS NORGESTIMATE; FINASTERIDE; FLUTAMIDE; GLUCOCORTICOID; INSULIN SENSITIZING AGENT; METFORMIN; ORNITHINE DECARBOXYLASE INHIBITOR; PIOGLITAZONE; PREDNISONE; PROGESTERONE DERIVATIVE; ROSIGLITAZONE; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TROGLITAZONE; ANTIDIABETIC AGENT; SEX HORMONE BINDING GLOBULIN;

ACNE; AMENORRHEA; ANDROGEN SYNTHESIS; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOMENORRHEA; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; WEIGHT REDUCTION; ANOVULATION; BLOOD; FEMALE; HYPERANDROGENISM;

ANOVULATION; FEMALE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; THIAZOLIDINEDIONES;

EID: 33646501282     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605030-00005     Document Type: Review

References (195)

1. Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-91
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-82
3. Rodin DA, Bano G, Bland JM, et al. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998; 49: 91-9
4. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 310-4
5. Wijeyaratne CN, Balen AH, Barth JH, et al. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002; 57: 343-50
6. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002; 16 (2): 263-72
7. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61
8. Rosenfield RL. Current concepts of polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol 1997; 11 (2): 307-33
9. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-6
10. Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996; 11: 1884-91
11. Azziz R, Ehrmann D, Legro RS, et al. PCOS/Troglitazone Study Group: troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-32
12. Carmina E, Legro RS, Stamets K, et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 10: 267-80
13. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-60
14. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-15
15. Barnes RB, Rosenfield RL. The polycystic ovary syndrome: pathogenesis and treatment. Ann Intern Med 1989; 110 (5): 386-99
16. Michelmore KF, Balen AH, Dunger DB, et al. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999; 51: 779-86
17. Baumann EE, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinologist 2002; 1: 333-48
18. Ibáñez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86: 3595-8
19. Meirow D, Yossepowitch O, Rosler A, et al. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological sub-groups. Hum Reprod 1995; 10: 1951-6
20. Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998; 145 (1-2): 103-10
21. Acién P, Querada F, Matallín P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32-40
22. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999; 71 (2): 319-22
23. Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004; 53: 2353-8
24. Ehrmann DA, Rosenfield RL, Barnes RB, et al. Detection of functional ovarian hyperandrogenism in women with androgen excess, N Engl J Med 1992; 327: 157-62
25. Legro RS, Driscoll D, Strauss III JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome, Proc Natl Acad Sci USA 1998; 95 (25): 14956-60
26. Battaglia C, Regnani G, Mancini F, et al. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients: a pilot study. Hum Reprod 2002; 17: 771-6
27. Jahanfar S, Eden JA, Warren P, et al. A twin study of polycystic ovary syndrome. Fertil Steril 1995; 63: 478-86
28. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7
29. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98 (1A): 33S
30. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800
31. Fox R, Ryan A. Polycystic ovary syndrome: not ovarian, not simple, unkind. Hum Fertil (Camb) 2002; 5 (1): S28-32
32. Achard C, Thiers J. Le virilisme pilaire et son association à l'insuffisance glycolytique (diabete des femmes à barbe). Bull Acad Natl Med 1921; 86: 51-64
33. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans: insulin receptor disorders in man. N Engl J Med 1976; 294: 739-45
34. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 5: 113-6
35. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991; 12 (1): 3-13
36. Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-66
37. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-6
38. Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-9
39. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74
40. Barbieri RL, Makris A, Ryan KJ. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril 1983; 40 (2): 237-41
41. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28 (2): 341-59
42. Cara JF, Rosenfield R. Insulin-like growth factor 1 and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988; 123: 733-9
43. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72 (1): 83-9
44. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633-67
45. Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581-6
46. Cibula D, Cífková R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785-9
47. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600
48. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of the risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 165-9
49. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095-105
50. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 7: 599-604
51. Despŕes JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7
52. Guzick DS, Talbott EO, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996; 17: 1224-32
53. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000; 73: 150-6
54. Atiomo WU, Bates SA, Condon JE, et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236-41
55. Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000; 52: 487-92
56. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54: 447-53
57. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-21
58. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 236 Suppl. 736: 13-22
59. Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005 Jul; 106 (1): 131-7
60. Hendarson CW. PCOS may lead to early onset of atherosclerosis even among thin women. Womens Health Wkly 2000; 11: 2-3
61. Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004; 175: 353-9
62. Paradisi G, Steinberg HO, Shepard MK, et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003 Feb; 88 (2): 576-80
63. Hube F, Birgel M, Lee YM, et al. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1999; 29: 672-8
64. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14
65. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992; 12: 1789-97
66. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-4
67. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 2453-5
68. Boulman N, Leiba LR, Shachar S, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-5
69. Villuendas G, San Millan JL, Sancho J, et al. The -597 G→A and -174 G→C polymorphisms in the promoter of the interleukin 6 gene (IL6) are associated with hyperandrogenism J Clin Endocrinol Metab 2002; 87: 1134-41
70. González F, Thusu K, Rahman EH, et al. Elevated serum levels of tumor necrosis factor α in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48: 437-41
71. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, et al. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004; 89: 806-11
72. Fain JN, Bahouth SW, Madan AK. TNF release by the nonfat cells of human adipose tissue. Int J Obes 2004; 28: 616-22
73. Sayin N, Gücer F, Balkanli-Kaplan P, et al. Elevated serum TNF-α levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003; 48: 165-70
74. Gonzalez F, Minium J, Rote NS, et al. Hyperglycemia alters tumor necrosis factor-α release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (9): 5336-42
75. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86: 2027-31
76. Ciaraldi TP, El-Roeiy A, Madar Z, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75: 577-83
77. Dunaif A, Wu X, Lee A, et al. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281: E392-9
78. Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-10
79. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-6
80. Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288 (5): E1047-54
81. Legro RS, Driscoll D, Strauss III J, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95: 14956-60
82. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996; 66: 942-7
83. Legro RS, Bentley-Lewis R, Driscoll D, et al. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002; 7: 2128-33
84. Yidiz BO, Yarali H, Oguz H, et al. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. Clin Endocrinol Metab 2003; 88: 2031-6
85. Ehrman DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 66-71
86. Sam S, Legor RS, Bentley-Lewis R, et al. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005 Aug; 90: 4797-802
87. Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68 (6): 1027-32
88. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141-54
89. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-11
90. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989; 31: 757-63
91. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60: 241-9
92. Sattar N, Hopkinson ZE, Greer IA. Insulin-sensitising agents in polycystic ovary syndrome. Lancet 1998; 351 (9099): 305-7
93. Nestler JE. Should patients with polycystic ovarian syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 2002; 17: 1950-98
94. Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 209-15
95. Loverro GF, Lorusso G, De Pergola G, et al. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002; 16: 3217-24
96. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82 (7): 2108-16
97. Hasegawa I, Murakawa H, Suzuki M, et al. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999; 71 (2): 323-7
98. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2000; 27: 583-95
99. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002; 3: 1177-89
100. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18: 1928-32
101. Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812-9
102. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951-6
103. Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Chichester: John Wiley & Sons, Ltd, 2004
104. Stamets K, Taylor DS, Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 630-7
105. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82: 421-9
106. Barbieri RL, Gargiulo AR. Metformin for the treatment of the polycystic ovary syndrome. Minerva Ginecol 2004; 56: 63-79
107. Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep 2004; 4 (1): 69-75
108. Norman RJ, Noakes M, Wu R, et al. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10: 267-80
109. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705-12
110. Kidson W. Polycystic ovary syndrome: a new direction in treatment. Med J Aust 1998; 169: 537-40
111. Jakubowicz DJ, Nestler JE. 17 alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556-60
112. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-9
113. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44: 611-6
114. Van Dam EW, Roelfsema F, Veldhuis JD, et al. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. Am J Physiol Endocrinol Metab 2002; 282: E865-72
115. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-804
116. Liu S, Willett WC, Manson JE, et al. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr 2003; 78: 920-7
117. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348: 2082-90
118. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998; 49: 235-61
119. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004; 19: 2474-83
120. Lebovitz HE. Oral antidiabetic agents. Med Clin North Am 2004; 88: 847-63
121. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-30
122. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-6
123. Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618-25
124. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9
125. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001; 52: 239-57
126. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 26: 867-72
127. Seedorf U, Assmann G. The role of PPAR alpha in obesity. Nutr Metab Cardiovasc Dis 2001; 11: 189-94
128. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12
129. U.S. Department of Health and Human Services. Rezulin to be withdrawn from the market. HHS News 2000 Mar 21; P00-8
130. Frias JP, Yu JG, Kruszynska YT, et al. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000; 23: 64-9
131. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93
132. Maggs DG, Burant CF, Buchanan TA, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 1998; 128: 176-85
133. Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827-31
134. Thyer C, Brzyski R, Easton C, et al. A comparison of the effect of metformin and rosiglitazone on insulin action and secretion in women with polycystic ovary syndrome. Fertil Steril 2002; 78 (3 Suppl. 1): S105-6
135. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18: 1210-8
136. Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835-40
137. Belli SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 624-9
138. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60-5
139. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone use in polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 5090-1
140. Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J Biol Chem 2001; 276: 16767-71
141. Mitwally MF, Witchel SF, Casper RF. Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 2002; 9: 163-7
142. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-306
143. Azziz R, Ehrmann DA, Legro RS, et al. PCOS/Troglitazone Study Group: troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 927-37
144. Mitwally MFM, Kusen NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Human Reprod 1999; 14 (11): 2700-3
145. Legro RS, Azziz R, Ehrmann D, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88: 5137-44
146. Ye JM, Doyle PJ, Iglesias MA, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001; 50: 411-7
147. GlaxoSmithKline Pharmaceuticals. Avandia (rosiglitazone maleate) [package insert]. Philadelphia (PA): GlaxoSmithKline Pharmaceuticals, 2000
148. Kalyoncu NI, Yaris F, Ulka C, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicology 2005; 19: 563-4
149. Zheng Z, Li M, Lin Y, et al. Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2002; 37: 271-3
150. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893-902
151. Dereli D, Dereli T, Bayraktar F, et al. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005; 52: 299-308
152. Cataldo N, Abbasi F, Mclaughlin T, et al. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001; 76: 1057-9
153. Cataldo A, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod 2006 Jan; 21: 109-20
154. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003 Feb; 10 (2): 99-104
155. Tarkun I, Cetinarslan B, Turemen E, et al. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153 (1): 115-21
156. Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006 Jan; 21: 121-8
157. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-43
158. Takeda Pharmaceuticals America, Inc. Actos (pioglitazone hydrochloride) [package insert]. Lincolnshire (IL): Takeda Pharmaceuticals America, Inc, 2000
159. Guido M, Romualdi D, Suriano R, et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004; 19: 534-9
160. Coffler MS, Patel K, Dahan MH, et al. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003; 88: 5624-31
161. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005 Mar; 90 (3): 1360-5
162. Ortega-Gonzalez C, Cardoza L, Coutino B, et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005 Jan; 184 (1): 233-9
163. Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 115: 125-33
164. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-8
165. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702
166. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-92
167. De Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863-71
168. Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470-4
169. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802
170. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283-90
171. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
172. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633-8
173. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93
174. Banerji M, Lebovitz H, Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus [abstract]. Diabetes 2001; 50 Suppl. 2: A90
175. Mori Y, Murokawa Y, Okada Y, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22: 908-12
176. Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid
177. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80: 2057-62
178. Moghetti P, Castello R, Negri C, et al. Meformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-46
179. Watkins PM, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-7
180. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001; 16: 1995-8
181. Parke-Davis. Rezulin prescribing information. Morris Plains (NJ): Parke-Davis, Dec 1997
182. Bell DS. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115 Suppl. 8A: 20S-3S
183. Augstein P, Dunger A, Heinke P, et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun 2003; 304: 378-84
184. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2005; 54: 1150-6
185. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803
186. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-9
187. Juhl CB, Hollingdal M, Porksen N, et al. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88: 3794-800
188. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-22
189. Boyle PJ. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin Cardiol 2004; 27 (7 Suppl. 4): IV11-6
190. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71
191. Miles PD, Romeo OM, Higo K, et al. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678-83
192. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-10
193. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-54
194. Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-4
195. Takagi T, Yamamuro A, Tamita K, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002; 89: 318-22